Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Citizens & Northern Corp

Citizens & Northern Corp lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,811 shares of the medical equipment provider’s stock after acquiring an additional 610 shares during the quarter. Citizens & Northern Corp’s holdings in Zimmer Biomet were worth $1,353,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Exchange Traded Concepts LLC lifted its stake in shares of Zimmer Biomet by 3,043.1% during the 3rd quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock worth $173,000 after purchasing an additional 1,552 shares during the period. NBC Securities Inc. purchased a new position in Zimmer Biomet during the third quarter worth about $105,000. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Zimmer Biomet by 1.5% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,230 shares of the medical equipment provider’s stock worth $2,400,000 after buying an additional 337 shares during the period. Blue Trust Inc. grew its holdings in Zimmer Biomet by 165.3% in the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock valued at $187,000 after buying an additional 1,071 shares during the period. Finally, Border to Coast Pensions Partnership Ltd increased its stake in shares of Zimmer Biomet by 4.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock valued at $16,711,000 after acquiring an additional 6,623 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James reduced their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Price Performance

ZBH stock opened at $100.52 on Tuesday. The company has a market capitalization of $20.01 billion, a P/E ratio of 22.59, a PEG ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a fifty day moving average price of $106.34 and a 200-day moving average price of $107.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm posted $2.20 earnings per share. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.